Marvel Commences Final Study Required Prior to Initiating Human Trials

Marvel Commences Final Study Required Prior to Initiating Human Trials

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.

"This dog study is the last of the two key primary animal studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are now planning our Phase 1 human trials, likely to be conducted in Australia upon the successful conclusion of this study and the previously commenced 4-week rat GLP study."

"We look forward to the completion of the rat and dog GLP studies of MB-204, and entering human trials, prior to the end of Q3 2023," said Rod Matheson, CEO of Marvel Biosciences. "We believe the profile of MB-204 is well-suited to address our primary markets, specifically depression and Alzheimer's disease. Owing to the immediate effect of the compound, we are confident that it will show the active effects early on in our clinical program."

In the United States, it is estimated that one in ten senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies.

MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease and Alzheimer's disease, as well as leading to an improved ability to concentrate.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/159134

News Provided by Newsfile via QuoteMedia

MRVL
The Conversation (0)
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CSE:NUR

NuRAN Wireless Reports Audited Annual Financial Results

NuRAN Wireless Inc. (“NuRAN Wireless” or the “Company”) (CSE:NUR) (OTC:NRRWF) (FSE:1RN) , a leading supplier of mobile and broadband wireless solutions to connect the next billion, is pleased to announce its audited financial results for the twelve months ended October 31, 2018. All dollar amounts are expressed in Canadian currency.

NuRAN Wireless Inc.-Technology Leadership in the Making

Keep reading...Show less

Veritiv Completes Acquisition of Orora Packaging Solutions

Veritiv Operating Company, a leader in specialty packaging distribution, today announced it has completed its acquisition of Orora Packaging Solutions (OPS). 1

On September 3, 2024 , Veritiv announced it had entered into a binding agreement with Orora (ASX: ORA) to acquire their North American packaging and distribution business Orora Packaging Solutions.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Troy Minerals Submits Drilling Permit Application for Table Mountain Silica Project, British Columbia

Troy Minerals Submits Drilling Permit Application for Table Mountain Silica Project, British Columbia

Troy Minerals Inc. ("Troy" or the "Company") (CSE:TROY)(OTCQB:TROYF)(FSE:VJ3) is pleased to announce the submission of a drilling permit application for the Table Mountain Silica Project in British Columbia. This key milestone supports Troy's strategic plan to evolve from an exploration-focused company into a revenue-generating mining operation, with production anticipated in the near term

The permit application details a comprehensive drilling program, requesting approval for a program involving up to 34 drill holes in 2025, totaling approximately 1,700 meters of drilling in the first year, and an additional 20 holes planned in subsequent years, bringing the total to approximately 2,700 meters over the proposed five-year period, with provisions for additional exploration activities as needed. This phased approach enables Troy to methodically advance the Table Mountain project, ensuring alignment with both operational goals and market demand.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Hempalta Corp. Completes 100% Acquisition of Hemp Carbon Standard, Expanding Company's Leadership in Hemp Carbon Credits

Hempalta Corp. Completes 100% Acquisition of Hemp Carbon Standard, Expanding Company's Leadership in Hemp Carbon Credits

Acquisition strengthens Hempalta's capacity to scale carbon credit solutions while establishing strategic foundation for advancing biochar expansion initiatives

Hempalta Corp. (TSXV: HEMP) ("Hempalta" or the "Company") today announced its acquisition of the remaining 49.9% of Hemp Carbon Standard Inc. ("HCS"), granting Hempalta full ownership of the carbon credit platform.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Canadian Investment Regulatory Organization Trade Resumption - CH

Canadian Investment Regulatory Organization Trade Resumption - CH

Trading resumes in:

Company: Charbone Hydrogen Corporation

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
CHARBONE Hydrogen Secures Initial Tranche of US$6 Million in Convertible Notes

CHARBONE Hydrogen Secures Initial Tranche of US$6 Million in Convertible Notes

(TheNewswire)

Charbone Hydrogen Corporation

Funding Advances Two North American Green Hydrogen Facilities and Electrolyzer Orders
Green Hydrogen Production Scheduled to Commence Within Weeks

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Charbone Hydrogene finalise une premiere tranche de billets convertibles de 6 M $US

Charbone Hydrogene finalise une premiere tranche de billets convertibles de 6 M $US

(TheNewswire)

Charbone Hydrogen Corporation

Des fonds sont accordés à deux usines nord-américaines d'hydrogène vert et à des commandes d'électrolyseurs
La production d'hydrogène vert devrait débuter dans quelques semaines

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×